Takahata M., Shimakura M., Hori R., et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001; 45:312-5.
Ullmann U., Schubert S., Krausse R. Comparative in vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; 43 (Suppl C):33-6.
Schulin T., Wennersten C., Ferraro M., Moellering R. Jr., Eliopoulos G. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42:1520-3.
Gomez-Lus R., Adrian F., del Campo R., et al. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. Int J Antimicrob Agents 2001; 18:49-54.
Gillespie S., Billington O. Activity of BAY 12-8039 against mycobacteria. Proceedings of the 8th ICID9; 1998 May 15–18; Boston, USA. p.176.
Rivera-Martнnez E., Pйrez-Gonzбlez E., Garcнa M., Orrantia-Gradнn R., Hernбndez-Oliva G., Torres-Gutierrez Rubro A. Determination of the in vitro susceptibility of different strains of M.tuberculosis to BAY 12-8039 and other antituberculosis agents. Proceedings of the 8th ICID7; 1998 May 15–18; Boston, USA. p.173-4.
Nord C., Edlund C. Susceptibility of anaerobic bacteria to BAY 12-8039, a new methoxyquinolone. Clin Microb Infection 1997; 3 (Suppl 2):285.
MacGowan A., Bowker K., Holt H., Wootton M., Reeves D. BAY 12-8039, a new 8-methoxyquinolone: comparative in vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40:503-9.
Boswell F., Andrews J., Wise R., Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 (Suppl B):43-9.
Stass H., Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl B):83-90.
Ballow C., Lettieri J., Agarwal V., Liu P., Stass H., Sullivan J. Absolute bioavailability of moxifloxacin. Clin. Ther 1999; 21:513-22.
Wise R., Andrews J., Marshall G., Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43:1508-10.
Lubasch A., Keller I., Borner K., Koeppe P., Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44:2600-3.
Lettieri J., Vargas R., Agarwal V., Liu P. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin Pharmacokinet 2001; 40 (Suppl 1):19-25.
Stass H., Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 (Suppl 1):33-8.
Gehanno P., Stass H., Arvis P. Penetration of moxifloxacin (MXF) into sinus tissues following multiple oral dosing. Clin Microb Infection 1999; 5 (Suppl 3):138.
Soman A., Honeybourne D., Andrews J., Jevons G., Wise R. Concentrations of moxifloxacin in cerum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44:835-8.
Sullivan J., Lettieri J., Liu P., Heller A. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40 (Suppl 1):11-8.
Stass H., Halabi A., Delesen H. No dose adjustment needed for patients with renal impairment receiving oral BAY 12-8039 (M). Proceedings of the 38th ICAAC8; 1998 Sep 24–27; San Diego, USA. p.5.
Stass H., Kubitza D. No dose adjustment is needed for moxifloxacin (MOX) in subjects suffering from hepatic impairment (HI). Clin Microb Infection 1999; 5 (Suppl 3):291.
Zhanel G., Walters M., Karlowsky J., Laing N., Hoban D. Activity of free (unbound) fluoroquinolone serum concentrations versus multi-drug resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model. Proceedings of the 40th ICAAC6; 2000 Sept 17–20; Toronto, Canada. p.7.
Wright D., Brown G., Peterson M., Rotschafer J. Application of fluoroquinolones pharmacodynamics. J Antimicrob Chemother 2000; 46:669-83.
Murray B. The growing threat of penicillin-resistant Streptococcus pneumoniae. Infect Dis Clin Pract 1997; 6:S21-S27.
Fogarty C., Grossman C., Williams J., Haverstock D., Church D. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16:748-63.
Hoffken G., Meyer H., Sprenger K., Verhoef L. Efficacy and safety of moxifloxacin (MXF) vs clarithromycin (Clarithro) for the treatment of community-acquired pneumonia (CAP). J Antimicrob Chemother 1999; 44 (Suppl A):127.
Petipretz P., Arvis P., Marel M., et al. Oral moxifloxacin versus high-dosage amoxycillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119:185-95.
Krasemann C., Meyer J., Springsklee M. Moxifloxacin (MXF) in community-acquired pneumonia (CAP) – a bacteriologic and clinical meta-analisis. Clin Microb Infection 1999; 5 (Suppl 3):139.
Chodosh S., DeAvate C., Haverstock D., Aneiro L., Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Resp Med 2000; 94:18-27.
Wilson R., Kubin R., Ballin I., et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44:501-13.
Schaberg T. Comparative effect of moxifloxacin and co-amoxiclav in the treatment of AECB. Clin Microb Infection 2000: 6 (Suppl 1):135.
Kreis S., Herrera N., Golzar N., et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Management 2000; 7: 33-7.
DeAbate C., Mathew C., Warner J., Heyd A., Church D. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029-37.
Krasemann C., Meyer J., Springsklee M. Moxifloxacin (MXF) in acute exacerbations of chronic bronchitis (AECB) – a bacteriologic and clinical meta-analisis. Clin Microb Infection 1999; 5 (Suppl 3):139.
Burke T., Villanueva C., Mariano H. Jr., et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther 1999; 21:1664-77.
Siegert R., Gehanno P., Nikolaidis P., et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000; 94:337-44.
Krasemann C., Meyer J., Springsklee M. Moxifloxacin (MXF) in acute sinusitis (AS) – a bacteriologic and clinical meta-analisis. Clin Microb Infection 1999; 5 (Suppl 3):139.
Parish L., Heyd A., Haverstock D., Church D. Efficacy and safety of moxifloxacin versus cephalexin in the treatment of mild to moderate acute uncomplicated skin and skin structure infections. J Antimicrob Chemother 1999; 44 (Suppl A):137.
Leal del Rosal P., Martinez R., Fabian G., et al. Efficacy and safety of moxifloxacin vs cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (uSSSI). J Antimicrob Chemother 1999; 44 (Suppl A):148.
Leal del Rosal P., Fabian G., Vick-Fragoso R. Efficacy and safety of moxifloxacin vs cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structures infections (uSSSI). Proceedings of the 39th ICAAC6; 1999 Sep 26–29; San Francisco, USA. p.716.
Heystek M., Tellarini M., Schmitz H., Krasemann C. Efficacy and safety of moxifloxacin (Мокси) vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl A):143.
Kubin R., Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. Proceedings of the 40th ICAAC6; 2000 Sep 17–20; Toronto, Canada. p.477.
Springsklee M., Reiter C., Meyer J. Safety and Tolerability Profile of Moxifloxacin (MXF). Clin Microb Infection 1999; 5 (Suppl 3):140.
Vohr H., Wasinka-Kempka G., Ahr H. Studies on the Phototoxic Potential of a new 8-Methoxyquinolone: BAY 12-8039. Proceedings of the 36th ICAAC6; 1996 Sep 15–18; New Orleans, USA. p.103.
Man I., Murphy J., Fergeson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 1999; 43 (Suppl B):77-82.
Ferguson J., Alajmi H., Kubin R., Dagget S., Saggu P. A double-blind, placebo- and lomefloxacin-controlled human volunteer phototest study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039). Proceedings of the 8th ICID7; 1998 May 15–18; Boston, USA. p.197.
Siepmann M., Kirch W. Tachycardia associated with moxifloxacin. BMJ 2001; 322:23.
Kubitza D., Delesen H. Influence of oral moxifloxacin on the QTs interval of healthy volunteers. Proceedings of the 40th ICAAC6; 2000 Sep 17–20; Toronto, Canada. p.475.
Hollister A., Haverstock D., Choudhri S. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concominant QTs prolonging drugs. Proceedings of the 40th ICAAC6; 2000 Sep 17–20; Toronto, Canada. p.476.
Beyer G., Hiemer-Bau M., Ziege S., Edlund C., Lode H., Nord C. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis 2000; 19:548-50.
Edlund C., Beyer G., Hiemer-Bau M., Ziege S., Lode H., Nord C. Comparative effects of moxifloxacin and clarithromycin on normal intestinal microflora. Scand J Infect Dis 2000; 32:81-5.
Stass H., Ochmann K. No significant interaction between oral moxifloxacin (MOX) and calcium supplements (CAS) in healthy volunteers (HV). J Antimicrob Chemother 1999; 44 (Suppl A):132.
Stass H., Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet 2001; 40 (Suppl 1):57-62.
Stass H., Boettcher M., Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet 2001; 40 (Suppl 1):39-48.
Stass H., Schuhly U., Wandel C., et al. Study to evaluate the interaction between oral moxifloxacin and sucralfate in healthy volunteers. Proceedings of the 39th ICAAC6. 1999 Sep 26–29. San Francisco. USA. p.2.
Sachse R., Stass H., Delesen H., et al. Lack of interaction between moxifloxacin and combined oral contraceptive steroids. Clin Microb Infection 1999; 5 (Suppl 3):141.
Stass H., Frey R., Kubitza D., Moller J.-G., Zuhlsdorf M. Influence of orally administered moxifloxacin (MOX) on the steady pharmacokinetics (PK) of digoxin (D) in healthy mail volunteers. J Antimicrob Chemother 1999; 44 (Suppl A):134.
Stass H., Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet 2001; 40 (Suppl 1):63-70.
Muller F., Hundt H., Muir A., et al. Study of the influence of once-daily 400 mg BAY 12-8039 (M) given once daily to healthy volunteers on PK and PD of warfarin (W). Proceedings of the 38th ICAAC6; 1998 Sep 24–27; San Diego, USA. p.4.
Синопальников А., Страчунский Л. Новые рекомендации по ведению взрослых пациентов с внебольничной пневмонией. Клин микробиол антимикроб химиотер 2001; 3(1): 54-68.